EVO
NASDAQ
DE
Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share
$2.59
▲ +$0.05
(+1.97%)
Vol 89K
6
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$967.5M
ROE
-18.1%
Margin
-21.0%
D/E
60.57
Beta
1.24
52W
$5–$9
Wall Street Consensus
13 analysts · Apr 20263
Strong Buy
5
Buy
5
Hold
0
Sell
0
Strong Sell
61.5%
Buy Rating
Price Chart
Earnings
Beat rate: 0.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2025 | $-0.12 | $-0.12 | $0.00 |
| Jun 2025 | $-0.20 | $-0.24 | $-0.04 |
| Dec 2024 | $0.01 | $-0.23 | $-0.24 |
| Sep 2024 | $-0.11 | $-0.22 | $-0.11 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $184.9M | $221.2M | $200.0M | $171.2M | $163.9M |
| Net Income | -$39.6M | -$40.8M | -$31.6M | -$43.5M | -$43.1M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -16.9% | -16.9% | -16.9% | -16.9% | -18.1% | -18.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -25.4% | -20.0% | -20.0% | -20.0% | -21.0% | -21.0% |
| Gross Margin | 5.0% | 12.9% | 12.9% | 12.9% | 10.8% | 10.8% |
| D/E Ratio | 54.63 | 54.63 | 54.63 | 54.63 | 60.57 | 60.57 |
| Current Ratio | 1.58 | 1.58 | 1.58 | 1.58 | 2.12 | 2.12 |
Key Ratios
ROA (TTM)
-8.6%
P/S (TTM)
1.28
P/B
1.5
EPS (TTM)
$-0.90
Rev Growth 3Y
+8.9%
52W High
$9.33
52W Low
$4.90
$4.90
52-Week Range
$9.33
Financial Health
Free Cash Flow
-$89.0M
Net Debt
-$77.2M
Cash
$174.0M
Total Debt
$96.9M
As of Sep 30, 2025
How does EVO compare to Life Sciences Tools & Services peers?
Peer group: Small-cap Life Sciences Tools & Services ($300M+) · 25 companies
EVO valuation vs Life Sciences Tools & Services peers
P/E ratio
—
▼
0%
below
peers
(32.5)
vs Peers
vs Industry
Fair value
P/S ratio
1.3
▼
67%
below
peers
(3.8)
vs Peers
vs Industry
Undervalued
P/B ratio
1.5
▼
59%
below
peers
(3.7)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.5%)
vs Peers
vs Industry
Low yield
EVO profitability vs Life Sciences Tools & Services peers
ROE
-18.1%
▼
454%
below
peers
(-3.3%)
vs Peers
vs Industry
Weak
Net margin
-21.0%
▼
124%
below
peers
(-9.4%)
vs Peers
vs Industry
Weak
Gross margin
10.8%
▼
77%
below
peers
(48.0%)
vs Peers
vs Industry
Weak
ROA
-8.6%
▼
229%
below
peers
(-2.6%)
vs Peers
vs Industry
Weak
EVO financial health vs Life Sciences Tools & Services peers
D/E ratio
60.6
▲
66%
above
peers
(36.5)
vs Peers
vs Industry
Above avg
Current ratio
2.1
▼
37%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
1.2
▼
13%
below
peers
(1.4)
vs Peers
vs Industry
Less volatile
EVO fundamentals radar
EVO
Peer median
Industry
EVO profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
EVO vs peers: key metrics
Top Holders
Top 5: 2.63%Mubadala Investment Co PJSC
1.39%
$11.1M
Wellington Management Group…
0.54%
$4.3M
DCF Advisers, LLC
0.36%
$2.9M
WCM Investment Management, …
0.17%
$1.4M
ABC Arbitrage SA
0.17%
$1.3M
As of Dec 31, 2025
Latest News
What Is the Jevons Paradox and What Does It Mean for Micron …
Nasdaq · Apr 04
In Revolutionary Statement, Fidel Castro's Grandson Embraces "Capitalism With Sovereignty"
ZeroHedge · Mar 31
Gevo (GEVO) Capitalizing on Sustainable Racing Fuels Opportunity
Yahoo Finance · Mar 31
British fintech Revolut reports record annual profit as it gears up for …
CNBC · Mar 24
Revolut warns it risks backlash over support for energy-intensive AI and crypto
The Guardian · Mar 24